Developing a new antibody treatment for advanced lung cancer
Late-stage development and de-risking of a novel monoclonal antibody immunotherapy for EGFR-positive solid cancers
This study is looking at a new treatment called TIGA-001, which uses a special type of antibody to help your immune system fight advanced lung cancer, and if you're interested, you might have a chance to join future trials to see how well it works.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tigatx INC NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10919593 on NIH RePORTER |
What this research studies
This research focuses on creating a novel IgA-based monoclonal antibody, TIGA-001, aimed at treating advanced EGFR-positive non-small cell lung cancer (NSCLC). The approach leverages the body's neutrophils to target and destroy cancer cells more effectively. The research includes extensive laboratory testing to ensure the safety and efficacy of the treatment before it is tested in humans. Patients may have the opportunity to participate in upcoming clinical trials as the research progresses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced or metastatic EGFR-positive non-small cell lung cancer.
Not a fit: Patients with early-stage lung cancer or those without EGFR mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves survival and quality of life for patients with advanced lung cancer.
How similar studies have performed: Other research has shown promise in using monoclonal antibodies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Boston, United States
- Tigatx INC — Boston, United States (Active)
Researchers
- Principal investigator: Stern, Howard M — Tigatx INC
- Study coordinator: Stern, Howard M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.